Compare Novartis AG (NVS) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.4 (market cap $72.20B). The key difference: Novartis AG is far larger — about 3.7× Vanguard Intermediate Term Corporate Bond ETF's market cap, and Novartis AG pays a 3.31% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard Intermediate Term Corporate Bond ETF for 62 Days on average.
| NVS | VCIT | |
|---|---|---|
Market Cap | $268.57B | $72.20B |
Volume | 1,532,573 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $84.82 |
52-Week Low | $121.80 | $77.98 |
Typical Hold Time | 82 Days | 62 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $78.385, up 0.15% with a bearish technical signal from moving averages. The ETF maintains consistent $0.34 dividend payments and shows institutional interest with recent purchases by Engineers Gate Manager LP and HB Wealth Management. Technical indicators show mixed signals with RSI at neutral levels while ADX indicates strong trend momentum.
The ETF offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against competitors. However, the bearish technical outlook and interest rate sensitivity present near-term risks. Long-term income investors may find value in VCIT's investment-grade corporate bond exposure despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
